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Abstract 
 Hyperglycemia and insulin resistance are common in critically ill patients 
in the ICU, although they have not previously had diabetes.  It has been reported 
that pronounced hyperglycemia may lead to complications in such patients, and 
cause the reactive oxygen species (ROS) production, although controlled trial data 
are still lacking.  The current debatable issue, focusing on whether the intensive 
insulin therapy, aimed at normalizing blood glucose, may improve 
patients’prognosis. Then, the debate is mainly about the time to start the therapy, 
and target of blood glucose level. Therefore, this research is mainly designed and 
aimed at knowing the difference between intensive insulin therapy and 
conventional insulin therapy on the increase of  superoxide dismutase (SOD), 
decrease of cytokine production (TNF-α and IL-6), increase of albumin level, and 
event of SIRS 
 This study was carried out in a randomly pre and post-test control group 
design, involving 40 adult patients being nursed through the ICU Sanglah hospital 
Denpasar.  They were randomly assigned to receive intensive insulin therapy, in 
which blood glucose was decreased and maintained at the level between 80-110 
mg/dl, or conventional insulin therapy in which the insulin was infused only if the 
blood glucose level exceeded 215 mg/dl, decreased and maintained then at the 
level between 180-200 mg/dl. 
 The result of the study showed that there was (1) significant increase of 
SOD mean level (370. 70 vs 98.50 U/gHb, p=0.001);   (2)  no significant decrease 
of  TNF-α mean level; (3) significant decrease of IL-6 mean level (10.26 vs 2.25; 
p=0.023); (4) significant increase of albumin mean level ( 0.62 vs 0.22); (5) 
significant decrease of SIRS (10 % vs 40 %, p=0.000) on intensive insulin therapy 
group compared to conventional insulin therapy group. It can be concluded that 
intensive insulin therapy could maintain blood glucose level between 80 – 110 
mg/dl, increase SOD level, decrease IL-6 level, increase albumin level, and 
decrease SIRS on hyperglycemia in critically ill ICU patients.   
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Introduction 
 
 Critically ill patients being 
nursed through the ICU tend to have 
hyperglycemia, the so-called stress 
diabetes or newly diabetes, since 
such the anti-regulation hormones as 
epinephrine, nor-epinephrine, cate 
cholamine, and glucagons are 
removed.  Hyperglycemia may 
increase ROS through both 
enzymatic process, reaction of ox-
phos and ADPH-oxide, and non-
enzymatic process that generates 
gluco-oxidant and glycation.  SOD is 
an enzyme that functions as anti-
oxidant only if superoxide ion is 
produced in mitochondria.  It has 
been known that there is a close 
relation between hyperglycemia and 
immune dysfunction, particularly 
infection.  The ROS on 
hyperglycemia may activate 
transcription factor of NF-kB that 
stimulates the production of 
inflammatory cytokine, such as TNF-
α and IL-1.  With its otocrine and 
paratocrin effects, inflammatory 
cytokine may stimulate the other 
cytokine, IL-6.  Therefore, the 
inflammatory cascade systemically 
happened.  This may result in the 
decrease of albumin production in 
heart.  
 Insulin is considered to be the 
most rational anti-diabetes medicine 
recently because of its anabolic 
function.  However, it is frequently 
assumed to lead serious compli 
cations like hyperglycemia.  Besides, 
there is still a debatable issue about 
blood glucose level reached with 
insulin therapy. 
 
Research Methodology 
 This research was an 
experimental study which was 
carried out in a randomly pre and 
post-test control group design on 
intensive insulin therapy group and 
conventional insulin therapy group.  
 
Results and Discussion 
 
Superoxide Dismutase (SOD) 
Level on Intensive Insulin Therapy 
Group and Conventional Insulin 
Therapy Group 
 The result of the study 
showed that mean level of SOD on 
the pre-test of intensive insulin 
therapy was 1,084.90 ± 193.43 
U/gHb, and it was 1,049.40 ± 166.58 
on the pre-test of conventional 
insulin therapy.  On the Seventh day 
of the post-test on intensive insulin 
therapy, level of SOD was 1,455.60 
± 180.25 U/gHb, and it was 1,147.90 
± 165.42 U/gHb on the post-test of 
conventional insulin therapy. The 
result of the analysis of paired 
sample test showed that there was a 
significant increase on the mean 
level of SOD on the pre and post-test 
intensive insulin therapy to both 
groups (p=0.001). The result of the 
analysis of t test showed that there 
was a significant difference between 
the level of SOD on both the post-
test intensive insulin therapy and 
conventional insulin therapy, in 
which p=0.001.  Meanwhile, the 
increase of mean level of SOD (Δ 
SOD) on intensive insulin therapy 
group was 370.70 ± 163.35 U/gHb, 
and it was 98.50 ± 96.14 U/gHb on 
conventional insulin therapy group. 
 It can be then concluded that 
there was over production of 
superoxide ion on hyperglycemia.  In 
order to reduce the negative effect of 
the oxidative stress, a huge number 
of SOD level must be needed. This 
may lead to the decrease of ROS 
level and reach normal level of SOD 
 
TNF-α Level on Intensive Insulin 
Therapy Group and Conventional 
Insulin Therapy Group 
 The result of the study 
showed that level of TNF-α on the 
pre-test intensive insulin therapy 
group was 10.26 ± 7.22 pg/ml.  
Meanwhile, it was 8.15 ± 6.29 pg/ml 
on that of conventional insulin 
therapy group.  On the Seventh day 
of the post-test, TNF-α on intensive 
insulin therapy group was 7.28 ± 
2.77 pg/ml, meanwhile it was 8.78 ± 
4.48 pg/ml on conventional insulin 
therapy group.   On the basis of 
paired sample test, there was no 
significant difference on both 
intensive insulin therapy group 
(p=0.078) and conventional insulin 
therapy group (p=0.713).  
Furthermore, the result of t test on 
level of TNF-α on the post-test to the 
two groups showed that there was no 
significant decrease of level of TNF-
α (p=0.211).  Meanwhile, the result 
of t test on the mean level (Δ TNF-α) 
of TNF-α showed that there was no 
significant difference among the two 
groups, either (2.98 vs. 0.63, 
p=0.977) 
 This might be caused by the 
difficulty of finding the appropriate 
time to detect the existence of TNF-
α, the instability of TNF-α in blood, 
and such other risky factors as 
central obesity, alcohol consumption, 
and other uncontrollable genetic 
factors.  Besides, TNF-α production 
was influenced by many factors, 
such as stress or disease causing 
hyperglycemia of which treatment 
had not been perfect yet. 
 
IL-6 Level on Intensive Insulin 
Therapy Group and Conventional 
Insulin Therapy Group 
 The result of the study 
showed that level of IL-6 on the pre-
test intensive insulin therapy group 
was 23.21 ± 9.63 pg/ml, and it was 
20.35 ± 10.17 on conventional 
insulin therapy group.  The result of 
Kolmogorov-Smirnov’s normality 
test showed that the two groups were 
in normal distribution.  The result of 
t test showed that there was no 
significant difference among the two 
groups (p=0.366).  On the seventh 
day of the post-test, it was found that 
the post-test IL-6 level on intensive 
insulin therapy was 12.96 ± 7.81 
pg/ml.  In the meantime, the post-test 
IL-6 level on conventional insulin 
therapy group was 18.32 ± 7.11 
pg/ml.  The data also showed that 
there was a decrease of level of IL-6, 
either on intensive insulin therapy 
group or conventional insulin 
therapy group.  On paired samples 
test, it was found that there was a 
significant decrease of level of IL-6 
on intensive insulin therapy group 
(p=0.001), but not on conventional 
insulin therapy group (p=0.411).  
Then the result of the analysis of t 
test on the post-test IL-6 level 
showed that there was difference 
among the two groups.  The t test 
result on the decrease of mean value 
of IL-6 level (Δ IL-6) on the two 
groups showed a significant 
difference (10.25 vs. 2.02; p=0.023) 
 The above analysis or study 
indicated  different result due to the 
fact that on the conventional insulin 
therapy group blood glucose was 
maintained within hyperglycemia (80 
– 110 mg/dl), while blood glucose on 
intensive insulin therapy was 
maintained to normal limit so that 
the production of oxidative stress on 
conventional insulin therapy group 
was still higher than intensive insulin 
therapy group.  Therefore, the 
production of inflammatory mediator 
was higher on conventional insulin 
therapy group. 
 
Albumin level on Intensive 
Therapy Group and Conventional 
Insulin Therapy Group 
 Pre-test result of albumin 
level on intensive insulin therapy 
group was 2.75 ± 0.58 mg/dl, while 
it was 2.83 ± 0.43 on conventional 
insulin therapy group.  The post-test 
result of albumin level on intensive 
insulin therapy group was 3.38 ± 
0.40 mg/dl, while it was 3.06 ± 0.32 
mg/dl.  On the paired sample test, 
there was a significant increase on 
both intensive insulin therapy 
(p=0.001) and conventional insulin 
therapy (p=0.001).  The result of T 
test analysis on level of albumin after 
the insulin therapy (post-test) on the 
two groups showed a significant 
difference (p=0.009).  T test on the 
increase of mean albumin value (Δ 
Albumin) on the two groups showed 
that there was a significant difference 
among the two groups (0.62 vs. 0.22; 
p=0.001) 
 The different result was 
caused by such factors as 
hyperglycemia may improve 
permeability of blood vessel that 
makes the albumin move to the 
interstitial and forms 
mikroalbuminuria. Besides, 
hyperglycemia will increase the 
production of oxidative stress that 
may decrease the production of 
albumin in hearth. 
 
The Event of SIRS on Intensive 
Insulin Therapy Group and 
Conventional Insulin therapy 
group 
 The result of the study 
showed that there were 2 people (10 
%) who were in SIRS found on 
intensive insulin therapy group, 
while on conventional insulin 
therapy group; it was found 9 people 
(45 %).  After having analyzed using 
Fisher’s exact test, there was a 
significant decrease on the number of 
people who were in SIRS on the 
intensive insulin therapy group 
compared to conventional insulin 
therapy group (p=0.001).  Besides, 
the result of the analysis also showed 
that the Odds ratio of the event of 
SIRS was 0.136 in which the trust 
interval was 0.025 – 0.748.  
Meanwhile, the relative risk to the 
event of SIRS on the two groups was 
0.222 in which the trust interval was 
0.055 – 0.902. 
 This event happened because 
on conventional insulin therapy 
group, blood glucose was maintained 
at the level of hyperglycemia.  This 
may improve the production of 
reactive oxygen mixture as oxidative 
stress that may activate NF-kB and 
stimulate the production of pro-
inflammatory cytokine, such as TNF-
α, IL-1, and IL-6 Moreover, 
hyperglycemia may cause the 
decrease of fagositic function of 
fagosit cell. 
 
Novelty 
1. Intensive insulin therapy on 
hyperglycemia can regulate 
blood glucose quickly so that 
it can increase the production 
of anti-oxidant; decrease the 
production of IL-6, increase 
level of albumin, and 
decrease event of SIRS. 
2. SOD enzyme as anti-oxidant 
increased higher after the 
infusion of intensive insulin 
therapy rather than 
conventional insulin therapy. 
 
Conclusion 
 Intensive insulin therapy on 
hyperglycemia is better than 
conventional insulin therapy.  It can 
decrease the production of ROS to a 
lower level.  Therefore, level of SOD 
increases. It can decrease the 
production of inflammatory cytokine 
like IL-6 so that it can decrease the 
event of SIRS, improve permeability 
of blood vessel, reduce the 
divulgence of albumin, so that it 
improves patients’ clinical outcome.  
Besides, there is no significant 
difference on complication of 
hyperglycemia by intensive insulin 
therapy. 
 
Suggestion/Recommendation 
1. Further research or study is 
needed with the same 
methodology in order to 
know the role of ROS on the 
production of other 
mediators, such as NO, 
ICAM, VICAM, and VEGF 
giving negative impact to 
endotil 
2. Research variables should be 
sustainably checked in 
accordance with betterment 
of disease, so that the 
accurate data of clinical 
output, regarding cause and 
effect relation of those 
variables, can be acquired. 
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